Method for therapeutic angiogenesis
The present invention relates to the E2 EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by any UCP activity inhibitor selected from a group consisting of a small interfering RNA (RNAi), an antisense oligonucleotide, and a polynucleotide complementarily binding to mRNA of UCP, a peptide, a peptide mimetics and an antibody, and a low molecular compound. In the meantime, the increase of angiogenesis is accomplished by the following mechanism; UCP over-expression is induced by a gene carrier and thus endogenous VHL is reduced, leading to the stabilization of HIF-1α which enhances VEGF activation based on the HIF-1α stabilization. The method for regulating UCP activity or level results in the increase or decrease of VHL activity or level, so that it can be applied to the development of an anticancer agent and an angiogenesis inducer.
1. A method for treating ischemic diseases, including the step of administering a pharmaceutically effective dosage of an expression vector with the insertion of E2-Endemic pemphigus foliaceus Ubiquitin carrier protein (E2-EPF UCP) gene, or a E2-EPF UCP protein to the subject.
2. The method according to claim 1 , wherein the E2-EPF UCP gene or the E2-EPF UCP protein reduces Von Hippel-Lindau (VHL) activity or level.
3. The method according to claim 1 , wherein the E2-EPF UCP gene or the E2-EPF UCP protein increases Hypoxia-inducible factor (HIF) stability.
4. The method according to claim 1 , wherein the E2-EPF UCP gene or the E2-EPF UCP protein increases expression of angiogenesis factors.
5. The method according to claim 4 , wherein the angiogenesis factor is a vascular endothelial growth factor (VEGF).